Clinical trials: Management of Anticoagulation
Healthy
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of PER977 followed by a one-week washout and…
- Trial name
- NCT02206087
- Testing
- PER977, Heparin Sodium
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects.
- Trial name
- NCT07024160
- Testing
- MT1011
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Atrial Fibrillation, Stroke
A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF
This is a prospective, single-arm, feasibility pilot study of 20 participants (aged 60 years or older, with additional stroke risk factors and 'actionable' undertreated AF) recruited from a total of 4 retail and outpatient…
- Trial name
- APOTHECARYAF (NCT04907825)
- Testing
- Oral anticoagulant
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Management of Anticoagulation
Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care
Patients who receive a mechanical heart valve to replace a diseased heart valve must take an anticoagulation medicine the rest of their lives, and monitor their level of anticoagulation.
- Trial name
- NCT00703963
- Testing
- INRatio monitor by Hemosense, Usual Care
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic